Investigator Sponsored Studies

Supporting Investigator Research

Click Here to Apply

Alkermes seeks to support investigator research designed and conducted by independent physicians and scientists. Alkermes has supported more than 40 clinical trials since the beginning of the ISS program in 2008. Alkermes can provide VIVITROL®, ARISTADA® and/or placebo to the ISS programs it supports. In addition, there may be limited financial support available. In general, the research we support is based in the U.S. with experienced researchers who have an established history of successfully receiving independent funding. If you have a “drug only” request and are seeking funding from a source outside Alkermes, we strongly recommend you submit a concept to Alkermes for review ahead of submitting your funding request.

Areas of Interest

Substance Use Disorders

  • Improving treatment initiation and adherence in AUD/OUD
  • Long-term treatment outcomes, including real world data in AUD/OUD
  • Neurologic profile of early recovery in OUD, including but not limited to sleep, cognition, and craving
  • Digital technologies for assessment of physiological parameters (e.g. wearables) and/or treatment access and outcomes (e.g. telehealth) in AUD/OUD
  • Implementing medication for AUD in healthcare systems

Schizophrenia

  • Reduction in social burden (e.g. family, treatment team) through use of LAIs
  • Demonstration of LAI benefits in specific comorbidities of schizophrenia (e.g. persistent substance problems) or subpopulations (e.g. persons with schizophrenia over the age of 60)
  • Short-term and long-term economic and clinical outcomes of LAI treatment in schizophrenia using real-world data

ISS applications are reviewed by a cross functional team of medical and scientific staff to consider patient safety, operational feasibility, scientific merit, and alignment with Alkermes research goals and needs. Applications can be submitted in one of two ways:

  • A pre-protocol submission where your application will serve as your proposal, but you have not developed a protocol yet; or
  • A protocol submission where your protocol is already developed and ready for review. To complete an application, please login here.

Please be aware that Alkermes cannot guarantee support for ISS program applications and all decisions regarding such support will be made at Alkermes’ sole discretion. ISS submissions are accepted on a rolling submission basis.

Request for Proposals (RFPs)

Alkermes will announce a Request for Proposals (RFP) for research in key clinical areas where gaps in data have been identified. Each RFP will focus on areas where Alkermes support could potentially have the greatest impact on improved patient care and outcomes.

Grants awarded as a result of an RFP are awarded solely for the purpose of advancement of basic research or enhancement of disease understanding or clinical outcomes.

Please note that all submissions in response to an RFP should be in concept form. Full proposals will be requested once the initial review has been completed. Include “RFP” in the study title when submitting through the portal.

Financial support for the RFPs below is limited to $300,000 USD, inclusive of indirect costs.

Requests must be submitted online at https://ISS.Alkermes.com by the physician or scientist.

Submissions should be in concept form. Full proposals will be requested once the initial review has been completed. Select “Clinical – RFP” as the study type when submitting through the portal. Please be aware that Alkermes cannot guarantee support for RFP program applications and all decisions regarding such support will be made at Alkermes’ sole discretion.

The RFPs listed below support small, innovative research projects for up to 2 years. No preliminary data is required.

There are no open RFPs at this time. If you would like to be notified when new RFP topics are posted please email ISS@alkermes.com.

Please contact ISS@alkermes.com with questions on the program.